by The global non-opioid pain treatment market has grown significantly in recent years due to the increasing prevalence of chronic pain disorders and growing preference for non-addictive alternatives to opioid drugs among patients and physicians. Non-opioid drugs offer effective treatment options for pain management without major side effects associated with opioids such as risk of addiction, dependence, and overdose. Some key non-opioid drugs used in pain management include acetaminophen, NSAIDs, DNRI’s, anticonvulsants, CAP agents, and others.
The Global Non Opioid Pain Treatment Market is estimated to be valued at US$ 43.67 Bn in 2024 and is expected to exhibit a CAGR of 8.1% over the forecast period 2024 To 2031.
Key Takeaways
Key players operating in the global non-opioid pain treatment are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd. , Sun Pharmaceutical Industries Ltd., Cipla Inc., Fresenius Kabi AG , GSK, Vertex Pharmaceuticals Incorporated, Pacira BioSciences, Collegium Pharmaceuticals, Cara Therapeutics. Pfizer Inc. is one of the leading players in the market with their branded drugs like Lyrica and Celebrex. Teva Pharmaceutical Industries Ltd. offers a wide range of generic medicines for pain management.
The Global Non Opioid Pain Treatment Market Demand is expected to witness significant growth due to the growing prevalence of chronic pain disorders and rising geriatric population globally which are more prone to pain related conditions. According to Global Burden Disease Study 2017, low back pain, neck pain and other musculoskeletal disorders are among the top reason for disability worldwide. The rising economic burden of chronic pain on healthcare systems further fuels the demand for effective non-opioid treatment options.
The non-opioid pain treatment market is expanding globally with a number of regional players emerging in developing economies. The large unmet need, growing awareness about hazards of opioid drugs along with rising accessibility to healthcare is expected to drive the adoption of non-opioid analgesics especially in Asian countries. Players are developing novel therapeutic formulas with improved safety profiles and targeting developing pain markets for future growth.
Market Key Trends
The key trend gaining traction in the non-opioid pain treatment market is the increasing popularity of combination therapies. Many clinical trials evaluating combination of different non-opioid modalities like NSAIDs, antidepressants, and anticonvulsants are reporting better efficacy in managing types of pain like fibromyalgia, back pain and osteoarthritis with reduced incidence of side effects. This synergistic approach is poised to emerge as a mainstream treatment strategy. The multi-targeted mechanisms enable addressing pain signals at different levels of neurological pathways for superior pain relief compared to single drug administration.
Porter’s Analysis
Threat of new entrants: The non-opioid pain treatment market requires significant research and development investments as well as regulatory compliances which make the entry of new players difficult.
Bargaining power of buyers: The bargaining power of buyers is moderate as there are many established brands for pain management treatments. However, the need for effective alternatives to opioids increases the bargaining power of buyers.
Bargaining power of suppliers: Established drug manufacturers have significant bargaining power over suppliers of raw materials due to their large procurement volumes and investment capabilities.
Threat of new substitutes: Ongoing research aims to develop new non-addictive alternatives which can substitute opioids for pain treatment. This poses a moderate threat of substitution.
Competitive rivalry: The non-opioid pain treatment market is highly competitive with major brands differentiating through novel drug delivery systems and therapies.
Geographical Regions: North America dominates the non-opioid pain treatment market currently accounting for over 40% of the global value due to the high prescription volumes of pain medications in the US. China is expected to be the fastest growing regional market between 2024-2031 supported by expanding medical infrastructure as well as increased generic drug production.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
